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High-accuracy proteome maps of human body fluids
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Abstract
The proteomes most likely to contain clinically useful disease biomarkers are those of human
body fluids. Three recent large-scale proteomic analyses of tears, urine and seminal plasma using
the latest mass spectrometric technology will provide useful datasets for biomarker discovery.
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Over the past decade, thousands of articles using the term
‘proteome’ in their title have been published, yet not a single
proteome has been comprehensively identified. Each piece
of work has typically identified a rather small and biased
subset of the proteome under study. With the emergence of
methods of quantitative proteomics based on mass spectro-
metry (MS) [1-4], which have improved both the value of
quantitative comparisons and the fraction of the proteome
measured, there is an even greater need for comprehensive
proteome analyses to use as baseline standards. In studies in
which multiple samples are being quantitatively compared,
for example in time-course experiments, the whole
proteome, or at least a consistent and reproducible subset
thereof, needs to be detectable and identifiable in order to
avoid an apparent falling-off in the number of different
polypeptides measured in successive samples. In addition,
the extensive pre-fractionation required to detect low-
abundance proteins typically generates ten or more peptide
mixtures per sample, each requiring several hours of MS
analysis time and creating significant data-analysis
overheads. This limits the application of any type of ‘shotgun
proteomics’ approach to high-throughput screening.
Current MS-based proteomic methods sample a limited
subset of a proteome in a relatively random manner; this
means that neither complete nor reproducibly defined
subproteomes are usually analyzed. We have proposed that
proteomics research should be divided into two phases - a
mapping phase and a scoring phase [5,6]. In the mapping
phase, all the proteins and peptides detectable by current
technology - ideally all the polypeptides present in a sample -
would be confidently identified and the data organized into
an easily accessible and searchable database. Initial
implementations of such databases include the Global
Proteome Machine [7,8] and the Peptide Atlas [9,10]. In the
scoring phase, a set of peptides representing the whole
proteome, or a consistent subset of particular interest, is
identified in the database and measured in samples by one of
a number of targeted analytical methods [3,11-13]. The
recent publication of three high-quality proteomic analyses
of human body fluids - tears, urine and seminal plasma - by
Matthias Mann and his colleagues [14-16], along with papers
describing large, high-quality datasets of serum [17,18] and
yeast [9] proteomes, are significant steps in the mapping
phase of this strategy.
Improvements in mass spectrometry
Until recently, the vast majority of proteomic data were
collected using ion-trap mass spectrometers, instruments
that are extremely robust but have only moderate mass
accuracy and resolution. An important consequence of this
low mass accuracy is the informatics challenge of assigning
peptide sequences to the fragment-ion spectra with high
confidence. The recent introduction of mass spectrometers
with high mass accuracy has increased the confidence of
proteomic results and led to the development of data-
collection protocols specifically designed to reduce the
likelihood of false sequence assignment [19].
The large-scale analyses of tear-duct fluid, urine and seminal
plasma from Mann’s group [14-16] were done using thelatest generation of mass spectrometers. First, the complexity
of each sample was reduced by protein fractionation, by either
one-dimensional gel electrophoresis or reversed-phase
chromatography. After tryptic digestion of each fraction, the
resulting peptides were analyzed by liquid chromatography
followed by tandem mass spectrometry (LC-MS/MS) using
two types of high-performance hybrid mass spectrometer -
the linear ion trap - Fourier transform mass spectrometer
(LTQ-FT) or the linear ion trap-orbitrap mass spectrometer
(LTQ-orbitrap). 
Interestingly, the overlap of proteins identified from
identical samples with different instruments was less than
that from repeat analyses in the same instrument, and thus
several additional proteins were identified by combining the
datasets generated by the two instruments. The difference in
peptides identified can be explained by the fact that the two
instruments were operated in different cycle modes that
correspond to their physical characteristics. The LTQ-FT
instrument had a slower peptide-sequencing duty cycle than
the LTQ-orbitrap. This was compensated for by the higher
mass precision (< 3 ppm) and two consecutive stages of
fragmentation (MS3) that significantly increased confidence
in peptide identification [20]. In contrast, the LTQ-orbitrap
was set up for higher throughput, providing a larger number
of peptide-sequencing cycles per time period with only a
slightly lower mass accuracy (< 5 ppm). Using the LTQ-
orbitrap, identification of two different peptides was
required for confident identification of a protein, whereas
the combined MS/MS and MS3 data of a single peptide
identified by the LTQ-FT was considered sufficiently
informative to identify a protein with confidence [14-16].
This latter mode of scoring significantly increased the total
number of identified proteins, with most of the proteins
exclusively detected by the LTQ-FT being identified by a
single peptide. 
Thus, operating the two instruments in different modes
resulted in a reduced number of redundant protein
identifications and increased the coverage of the proteome.
The rate of false peptide assignments was evaluated by
submitting the MS data to a search against a decoy
database, in which the protein sequences had been
reversed [21], and was found to be very low. The results
show that the increased data quality generated by high-
performance instruments, compared with the commonly
used ion-traps, greatly facilitates the generation of high-
confidence datasets.
Proteomics and biomarker discovery
Among samples analyzed by proteomics, blood plasma and
other body fluids most clearly illustrate the need for
consistent, in-depth and high-throughput analysis, and thus
for the implementation of the two-stage proteomic strategy
outlined above. Proteomics has raised great expectations for
the discovery of biomarkers for improved diagnosis or
stratification of a wide range of diseases, including cancers
[22]. Blood plasma and other body fluids are expected to be
excellent sources of protein biomarkers because they
circulate through, or come in contact with, a variety of
tissues - with all tissues in the case of plasma. During this
contact they are likely to pick up proteins secreted or shed by
tissues, a hypothesis that has recently been tested and
confirmed [23].
The task of quantitatively analyzing the proteomes of
plasma and other body fluids is as daunting as it is
attractive, especially if many clinical samples have to be
processed in a single study. Human plasma has been
termed the most complex human proteome [24] and the
large differences in the concentrations of individual
proteins, ranging from several milligrams to less than one
picogram per milliliter, challenge current MS technology.
Another analytical challenge for biomarker discovery arises
from the high variability in the concentration and state of
modification of some human plasma proteins between
different individuals [25]. Therefore, samples from a large
number of individuals will have to be analyzed to control
for this variability. Despite these limitations, human
plasma holds immense diagnostic potential. Recently,
several large-scale projects have been initiated, aimed at
characterizing the human plasma proteome [9,17].
Although the coverage of the plasma proteome with high-
confidence identifications was disappointingly low [18],
these publicly available high-confidence datasets provide
helpful references for future targeted studies following a
proteome-scoring strategy.
As a considerable volume of blood circulates through all
organs in humans, it must be expected that proteins secreted
or released from a specific tissue or cell type - the proteins
that hold the highest potential as biomarkers - will be
diluted in plasma to a degree that frequently makes them
undetectable with current analytical methods. Interest has,
therefore, been focused on the analysis of so-called
‘proximal’ fluids, which have been in contact with only one
or a few tissue types, and for which less dilution of tissue-
derived proteins would be expected. Proximal fluids include
nipple aspirate, cerebrospinal fluid, bronchial lavage fluid,
as well as the urine, seminal plasma and tear fluid that are
the subject of the three recent papers from Mann’s group
[14-16]. These latter studies stand out because the powerful
new mass spectrometers have been applied in a consistent
manner to all three samples. The results are of excellent
quality and have increased the number of proteins identified
from the respective samples several fold compared with
previous studies, providing unprecedented insight into the
complexity of the proteome in these three body fluids. This
work, and similar studies that will undoubtedly follow,
should provide a rich source of information for the imple-
mentation of advanced proteome-scoring strategies.
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In spite of considerable effort and the application of state-of-
the art MS (as in [14-16]), none of the proteomes analyzed so
far can be considered to be completely mapped. Neverthe-
less, the extensive data collected enable interesting compari-
sons to be made that will guide the use of the datasets for
biomarker discovery. The proteins identified from the
different body fluids by Mann’s group [14-16] were
compared with each other and with a high-quality reference
list of peptide sequences already observed by MS in human
plasma [14]. The overlaps between the individual studies are
shown in Figure 1. Interestingly, more than half of the
proteins identified in seminal plasma and in tear fluid were
also identified in the urine dataset. The combined dataset
contains the impressive number of 2,130 unique protein
hits, but only 190 proteins were found in all three studies.
The urine proteome was analyzed most extensively; it
contained the highest number of exclusive proteins and
therefore represents the richest resource for biomarker
discovery of the three body fluids discussed here.
A comparison between the urine dataset and the latest
version (February 2006) of the public human plasma
Peptide Atlas database [9] showed that about two-thirds of
the urine proteins had already been detected in human
plasma using MS. As expected, most proteins exclusively
found in urine have very low concentrations in plasma
(215 ng/ml to 11 pg/ml) [26] and were therefore more
difficult to identify in this body fluid. For instance, the widely
used protein biomarker prostate-specific antigen (PSA;
Swiss-Prot accession number: P07288) was not included in
the large human plasma dataset, but could be unambiguously
detected in urine and in seminal plasma. Proteins exclusively
identified in urine include corticotropin-lipotropin (a
marker for pituitary tumors; Swiss-Prot: P01189), kallikrein
II (a marker for ovarian cancer; Swiss-Prot: Q9UBX7),
prostate secretory protein PSP94 (Swiss-Prot: P08118),
prostate acid phosphatase (Swiss-Prot: P15309) and
pancreatic secretory trypsin inhibitor (TATI, Swiss-Prot:
P00995). All these are already in use as clinical markers or
are being evaluated as biomarkers for prostate or pancreatic
diseases [26].
Looking to the future
The high number of proteins identified in urine, seminal
plasma and tear fluid suggests that differences in protein
concentrations in these samples are significantly less than in
plasma, making these body fluids easier to analyze by MS.
Although some proteins exclusively detected in urine were
not identified in plasma by MS-based methods, they were
detected in plasma by sensitive antibody-based approaches.
This underlines the fact that biomarkers discovered in other
body fluids can also be screened for in plasma [27]. The
major limitation of proximal fluid proteomes over that of
plasma is their lack of comprehensiveness, which restricts
their biomarker potential to particular diseases. In addition,
the limited dynamic range of current MS methods, even
those as advanced as the ones used by Mann and colleagues
[14-16], suggests that this proteome coverage is still
incomplete. New methods will have to be developed to
expand the detectable protein concentration range and
increase sample throughput.
Nevertheless, the protein datasets provided by Mann and
colleagues [14-16] significantly expand the proteome coverage
of urine, seminal plasma and tear fluid, and represent very
useful high-quality references for future proteome studies,
including targeted LC-MS/MS approaches. The datasets
represent an important step towards the implementation of
two-stage proteomic strategies in biomarker discovery.
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Figure 1
The numbers of proteins identified in urine, seminal plasma and tear fluid.
All overlaps of proteins (two-way and three-way) are shown for all three
datasets: urine (red), seminal plasma (blue) and tear fluid (green).
Numbers represent the number of shared proteins in the respective
overlapping and non-overlapping areas.
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